

Contents

WHO Expert Committee on Drug Dependence	v
Abbreviations	vii
Introduction	1
1. Briefings from international organizations on their work on the public health element of the world drug problem	3
1.1 Update from the International Narcotics Control Board	3
1.2 Update from the United Nations Office on Drugs and Crime	4
1.3 Update from the WHO Department of Essential Medicines and Health Products	6
1.4 Update from the WHO Department of Mental Health and Substance Abuse	7
1.5 Update from the WHO Department of HIV/AIDS	8
2. Principles for prioritizing and assessing substances as part of ECDD's work	10
3. Update from the first Informal Working Group of the ECDD	11
4. Follow-up on recommendations made by the ECDD at its thirty-seventh meeting	12
4.1 Acetylfentanyl	12
4.2 MT-45	12
4.3 para-Methoxymethylamphetamine (PMMA)	12
4.4 a-Pyrrolidinovalerophenone (a-PVP)	12
4.5 para-Methyl-4-methylaminorex (4,4'-DMAR)	13
4.6 Methoxetamine (MXE)	13
4.7 Phenazepam	13
5. Critical review of psychoactive substances	14
5.1 U-47700	14
5.2 Butyrfentanyl (butyrylfentanyl)	16
5.3 4-Methylethcathinone (4-MEC)	17
5.4 3-Methylmethcathinone (3-methyl-/V-methylcathinone; 3-MMC)	19
5.5 Ethylone (3,4-methylenedioxy-/V-ethylcathinone; bk-MDEA; MEDEC)	21
5.6 Pentedrone (a-methylaminovalerophenone)	22
5.7 Ethylphenidate (EPH)	24
5.8 Methiopropamine (MPA)	26
5.9 MDMB-CHMICA	27
5.10 5F-APINACA (5F-AKB-48)	29
5.11 JWH-073	31
5.12 XLR-11	33

6. Updates	35
6.1 Cannabis and cannabis resin	35
7. Follow-up on recommendations from international meetings and consultations	37
7.1 Follow-up on implementation of recommendations of UNGASS and of the UNODC-WHO Expert Consultation on NPS	37
7.2 WHO and other agencies' surveillance mechanisms and lists	39
8. Future agenda items	42
Acknowledgements	43
References	43